Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Medical University of Graz | OTHER |
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
The gastric barrier plays a major role in the maintanance of the distal intestinal microbiome composition. It has been shown before that the use of gastric acid suppression medication, such as proton pump inhibitors, are associated with distinctive alterations of the intestinal microbiome. Foremost, the invasion of predominantly oral bacteria, like Veillonella and Streptococcus species, were a resurring finding in previous reports.
Gastric cancer treatment includes the total or subtotal resection of the stomach which can influence the gastric acid production. However, the influence by alterations in gastric milieu after this treatment on the composition of the intestinal microbiome is not well studied.
Therefore, the intestinal microbiome of patients after total or subtotal gastrectomy and its influence on intestinal inflammation and gut permeability will be studied.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Test group | Patients who underwent total or subtotal gastrectomy for the treatment of gastric cancer | ||
| Control group 1 | Patients who underwent endoscopic mucosal resection/submucosal dissection for the treatment of gastric cancer | ||
| Control group 2 | In-house relatives of Test group and Control group 1 participants | ||
| Control group 3 | Patients with long-term history of proton pump inhibitor usage |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Intestinal microbiome composition | Significant differences in the beta-diversity of the intestinal microbiome between Test group and Control groups | 5 years after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Intestinal microbiome composition (II) | Significant differences in the alpha-diversity of the intestinal microbiome between Test group and Control groups | 5 years after surgery |
| Fecal calprotectin |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Test group: Patients with a history of gastric cancer surgery, without the current use of PPI and no recurrence of gastric cancer and a minimum of 12 months since the last adjuvant treatment Control group 1: Patients with a history of endoscopic resection of gastric cancer, without the current use of PPI and no recurrence of gastric cancer Control group2: Healthy volunteers recruited from relatives of study participants (Test group and Control group 1), without the current use of PPI Control group 3: Patients with a history of long-term PPI usage (6 months) without a history of gastric cancer
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Cancer Institute | Vilnius | Lithuania |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32504369 | Derived | Horvath A, Bausys A, Sabaliauskaite R, Stratilatovas E, Jarmalaite S, Schuetz B, Stiegler P, Bausys R, Stadlbauer V, Strupas K. Distal Gastrectomy with Billroth II Reconstruction is Associated with Oralization of Gut Microbiome and Intestinal Inflammation: A Proof-of-Concept Study. Ann Surg Oncol. 2021 Feb;28(2):1198-1208. doi: 10.1245/s10434-020-08678-1. Epub 2020 Jun 5. |
Not provided
Not provided
The use of sequence data repositories is planed
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013274 | Stomach Neoplasms |
| ID | Term |
|---|---|
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Significant differences in intestinal inflammation measured by fecal calprotectin between Test group and Control groups
| 5 years after surgery |
| Fecal zonulin | Significant differences in intestinal permeability measured by fecal zonulin between Test group and Control groups | 5 years after surgery |
| Serum LPS | Significant differences in serum LPS between Test group and Control groups | 5 years after surgery |
| Serum sCD14 | Significant differences in serum sCD14 between Test group and Control groups | 5 years after surgery |
| Serum LBP | Significant differences in serum LBP between Test group and Control groups | 5 years after surgery |
| Serum sCD163 | Significant differences in serum sCD163 between Test group and Control groups | 5 years after surgery |
| Serum sMR | Significant differences in serum sMR between Test group and Control groups | 5 years after surgery |
| Serum CRP | Significant differences in serum CRP between Test group and Control groups | 5 years after surgery |
| Serum DAO | Significant differences in serum DAO between Test group and Control groups | 5 years after surgery |
| D004066 |
| Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D013272 | Stomach Diseases |